No validated reference range is available for serum human MMP-13 in adults with knee osteoarthritis from the supplied UK guidance or literature. NICE CKS NICE NG226 Urbanek et al. 2026 Cerezo et al. 2024 Rannou et al. 2025
The supplied OA studies do not report serum MMP-13 concentrations or establish assay-specific healthy or OA reference intervals. Urbanek et al. 2026 Cerezo et al. 2024 Rannou et al. 2025
The only numerical MMP-13 data provided are from an in-vitro experiment in normal human articular chondrocytes, where unstimulated secretion was 211.3 pg/mL (IQR 196.7–318.9) and IL-40 exposure increased secretion to 409.3 pg/mL at 10 ng/mL, 801.8 pg/mL at 100 ng/mL, and 1008.0 pg/mL at 200 ng/mL; these values are not serum results and must not be used as a patient reference range. Cerezo et al. 2024
For a requested serum MMP-13 result, interpret only against the reporting laboratory’s assay-specific reference interval, analytical platform, units, and sample handling requirements; no clinically validated diagnostic or monitoring threshold for knee OA can be derived from this evidence. Urbanek et al. 2026 Cerezo et al. 2024 Rannou et al. 2025
Key References
- NICE CKS: Osteoarthritis
- NICE NG226: Osteoarthritis in over 16s: diagnosis and management
- SmPC: Bimzelx 160 mg solution for injection in pre-filled pen
- NICE NG100: Rheumatoid arthritis in adults: management
- SmPC: Bimzelx 320 mg solution for injection in pre-filled pen
- SmPC: Bimzelx 320 mg solution for injection in pre-filled syringe
- NICE NG203: Chronic kidney disease: assessment and management
- SmPC: Bimzelx 160 mg solution for injection in pre-filled syringe
- (Urbanek et al., 2026): Synovial Fluid as a Window into Early Cartilage Remodeling After Autologous Matrix-Induced Chondrogenesis.
- (Cerezo et al., 2024): IL-40 is up-regulated in the synovial fluid and cartilage of osteoarthritis patients and contributes to the alteration of chondrocytes phenotype in vitro.
- (Rannou et al., 2025): Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study.